454453-49-7
454453-49-7 結(jié)構(gòu)式
基本信息
2-[2,6-二硝基-4-(三氟甲基)苯基]-N-(4-氟苯基)肼基硫代甲酰胺
kobe2602
kobe 2602
kobe-2602
kobe2602, >96%
Kobe 2602, >=98%
KOBE 2602
KOBE-2602
2-[2,6-Dinitro-4-(trifluoroMethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioaMide
Hydrazinecarbothioamide, 2-[2,6-dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)-
kobe-2602 2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-15717 | KOBE-2602 Kobe2602 | 454453-49-7 | 50mg | 1050元 |
| 2024/11/08 | HY-15717 | KOBE-2602 Kobe2602 | 454453-49-7 | 10mM * 1mLin DMSO | 1155元 |
| 2024/11/08 | HY-15717 | KOBE-2602 Kobe2602 | 454453-49-7 | 100mg | 1680元 |
常見問題列表
| Target | Value |
|
Ras
() | 149 μM(Ki) |
Kobe2602 (2-20 μM; 1 hour) exhibits Ras-Raf-binding inhibition in NIH 3T3 cells.
Kobe2602 has IC
50
value of approximately 10 μM for the cellular Ras-Raf-binding inhibition.
Kobe2602 (20 μM) efficiently inhibits the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing H-Ras
G12V
.
Kobe2602 inhibits Ras?GTP but not Ras?GDP.
Kobe2602 (20 μM) inhibits the anchorage-dependent proliferation of H-rasG12V-transformed cells.
Cell Proliferation Assay
| Cell Line: | H-ras G12V -transformed NIH 3T3 cells |
| Concentration: | 20 μM |
| Incubation Time: | 24 hours , 48 hours, 72 hours |
| Result: | Efficiently inhibited colony formation in soft agar in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: | NIH 3T3 cells |
| Concentration: | 2 μM, 20 μM |
| Incubation Time: | 1 hour |
| Result: | Effectively reduced the amount of c-Raf-1 associated with H-Ras G12V in NIH 3T3 cells in a dose-dependent manner, indicating the inhibition of the cellular activity of Ras. |
Kobe2602 (80 mg/kg; p.o.; five consecutive days per week, for 17 days) exhibits antitumor activity on a xenograft of human colon carcinoma SW480 cells carrying the K-ras
G12V
gene.
| Animal Model: | Female athymic nude mice (6-8 wk old), with SW480 cells xenograft |
| Dosage: | 80 mg/kg |
| Administration: | Oral administration, five consecutive days per week, for 17 days |
| Result: | Caused inhibition of the tumor growth. |